Artificial Intelligence (AI) plays a pivotal role in drug discovery. In particular artificial neural networks such as deep neural networks or recurrent networks drive this area. Numerous applications in property or activity predictions like physicochemical and ADMET properties have recently appeared and underpin the strength of this technology in quantitative structure-property relationships (QSPR) or quantitative structure-activity relationships (QSAR). Artificial intelligence in de novo design drives the generation of meaningful new biologically active molecules towards desired properties. Several examples establish the strength of artificial intelligence in this field. Combination with synthesis planning and ease of synthesis is feasible and more and more automated drug discovery by computers is expected in the near future.
The Frontiers in Medicinal Chemistry (FiMC) is the largest international Medicinal Chemistry conference in the German speaking area and took place from April 3rd to 5th 2023 in Vienna (Austria). Fortunately, after being cancelled in 2020 and two years (2021–2022) of entirely virtual meetings, due to the COVID‐19 pandemic, the FiMC could be held in a face‐to‐face format again. Organized by the Division of Medicinal Chemistry of the German Chemical Society (GDCh), the Division of Pharmaceutical and Medicinal Chemistry of the German Pharmaceutical Society (DPhG), together with the Division of Medicinal Chemistry of the Austrian Chemical Society (GÖCH), the Austrian Pharmaceutical Society (ÖPhG), and a local organization committee from the University of Vienna headed by Thierry Langer, the meeting brought together 260 participants from 21 countries. The program included 38 lectures by leading scientists from industry and academia as well as early career investigators. Moreover, 102 posters were presented in two highly interactive poster sessions.
The cover picture shows bovine rhodopsin, the first G-protein-coupled receptor (GPCR) structure determined at atomic resolution. It is embedded into the cell membrane with the conserved seven transmembrane helices. Rhodopsin is unique among GPCRs due to its activation mechanism: The covalently bound ligand retinal (shown in red) undergoes a light-induced isomerization, thus activating the receptor. For other GPCRs intracellular responses are modulated by binding of extracellular signal molecules and drugs. Valsartan, fexofenadine, montelukast, and clapidogrel are examples of drug compounds acting on GPCRs that bind peptides, biogenic amines, lipids, and nucleotides, respectively. Further details can be found in the review article by Klabunde and Hessler on p. 928 ff.